BioNTech SE vs Merck & Company, Inc. — Stock Comparison
BioNTech SE (BNTX) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. clearly outscores BioNTech SE on Q·Score (7 vs 4.7 out of 10), led by Quality (7.7 vs 1.5) and Growth (6.2 vs 2.1). BioNTech SE scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for BNTX (+36.0%) than for MRK (+12.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-45% margin).
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BNTX vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus BioNTech SE (BNTX) at 4.7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BNTX or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 2.1/10). BioNTech SE reports revenue growth (-35.4% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BNTX or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.7/10 vs 6.4/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BNTX vs MRK?
There are 19 analysts covering BNTX with a consensus price target of $123.49, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BNTX or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 1.5/10). Net profit margin: BNTX at -44.6%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BNTX or MRK?
BioNTech SE (BNTX) scores higher on Financial Health (7.7/10 vs 7/10). Market beta: BNTX at 1.32, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BNTX and MRK?
BioNTech SE (BNTX) has a market capitalisation of $23.0B, while Merck & Company, Inc. (MRK) has a market cap of $283.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BNTX or MRK pay dividends?
BNTX does not currently pay a dividend, while MRK pays a dividend yield of 2.96%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →